

40/502115

ST Rec'd PCT/PTO 21 JUL 2004

WDN/DC:dm 07/20/04 4239-64126-13 295254

Express Mail No. EV514603234US

Date of Deposit: July 21, 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Deborah Philp, Hynda K. Kleinman, and Michael Elkin

Application No. _____

Filed: July 21, 2004

Confirmation No. _____

For: METHODS AND COMPOSITIONS FOR THE
PROMOTION OF HAIR GROWTH
UTILIZING ACTIN BINDING PEPTIDES

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 4239-64126-13

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

If the present application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55). Applicants will provide copies of such patents upon request.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a

10/502115
DTA Rec'd PCT/PTO 21 JUL 2004

WDN/DC:dm 07/20/04 4239-64126-13 295254


Express Mail No. EV514603234US
Date of Deposit: July 21, 2004
PATENT

fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
David Cash, Ph.D.
Registration No. 52,706

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	4239-64126-13
	Application Number	
	Filing Date	July 21, 2004
	First Named Inventor	Philp
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

NOTE: If this application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		4,297,276	10/27/1981	Goldstein et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 96/11016 A1	18.04.1996	Alpha 1 Biomedicals, Inc.

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Grant <i>et al.</i> , "Matrigel induces thymosin β 4 gene in differentiating endothelial cells," <i>J. Cell Science</i> 108:3685-3694 (1995).
		Huff <i>et al.</i> , " β -Thymosins, small acidic peptides with multiple functions," <i>Int. J. Biochem. Cell Biol.</i> 33:205-220 (2001).
		Kobayashi <i>et al.</i> , "Thymosin- β 4 regulates motility and metastasis of malignant mouse fibrosarcoma cells," <i>Am. J. Pathol.</i> 160:869-882 (2002).
		Lee <i>et al.</i> , "Hepatocyte growth factor (HGF) activator expressed in hair follicles is involved in <i>in vitro</i> HGF-dependent hair follicle elongation," <i>J. Dermatol. Sci.</i> 25:156-163 (2001).
		Lindner <i>et al.</i> , "Involvement of hepatocyte growth factor/scatter factor and Met receptor signaling in hair follicle morphogenesis and cycling," <i>FASEB J.</i> 14:319-332 (2000).
		Low <i>et al.</i> , "Complete amino acid sequence of bovine thymosin β 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations," <i>Proc. Natl. Acad. Sci.</i> 78:1162-1166 (1981).
		Low and Goldstein, "Chemical characterization of thymosin β 4," <i>J. Biol. Chem.</i> , 257:1000-1006 (1982).
		Malinda <i>et al.</i> , "Thymosin β 4 stimulates directional migration of human umbilical vein endothelial cells," <i>FASEB J.</i> 11:474-481 (1997).
		Malinda <i>et al.</i> , "Thymosin β 4 accelerates wound healing," <i>J. Invest. Dermatol.</i> 113:364-368 (1999).

EXAMINER SIGNATURE:	DATE CONSIDERED:
---------------------	------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket Number	4239-64126-13
Application Number	
Filing Date	July 21, 2004
First Named Inventor	Philp
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

Oh *et al.*, "Hepatocyte growth factor upregulates thymosin $\beta 4$ in human umbilical vein endothelial cells," *Biochem. Biophys. Res. Commun.* 296:401-405 (2002).

Oshima *et al.*, "Morphogenesis and renewal of hair follicles from adult multipotent stem cells," *Cell* 104:233-245 (2001).

Sato *et al.*, "Induction of the hair growth phase in postnatal mice by localized transient expression of Sonic hedgehog," *J. Clin. Invest.* 104:855-864 (1999).

Shapiro and Price, "Hair regrowth. Therapeutic agents," *Dermatol. Clin.* 16:341-356 (1998).

Taylor *et al.*, "Involvement of follicular stem cells in forming not only the follicle but also the epidermis," *Cell* 102:451-461 (2000).

Yano *et al.*, "Control of hair growth and follicle size by VEGF-mediated angiogenesis," *J. Clin. Invest.* 107:409-417 (2001).

DATE
CONSIDERED:

Information Disclosure Statement (1449) Page 2 of 2